Year: 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Intraoral Scanners Market to Grow by USD 915.75 Million (2024-2028), Driven by Enhanced Accuracy and Productivity with Advanced Technologies, AI Impacting Market Trends – Technavio

error: Content is protected !!